Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease - PubMed (original) (raw)
Review
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
André J Scheen. Clin Pharmacokinet. 2015 Jul.
Abstract
Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus. SGLT2 cotransporters are responsible for reabsorption of 90 % of the glucose filtered by the kidney. The glucuretic effect resulting from SGLT2 inhibition contributes to reduce hyperglycaemia and also assists weight loss and blood pressure reduction. Several SGLT2 inhibitors are already available in many countries (dapagliflozin, canagliflozin, empagliflozin) and in Japan (ipragliflozin, tofogliflozin). These SGLT2 inhibitors share similar pharmacokinetic characteristics with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites and a low renal elimination as a parent drug. Pharmacokinetic parameters are slightly altered in the case of chronic kidney disease (CKD). While no dose adjustment is required in the case of mild CKD, SGLT2 inhibitors may not be used or only at a lower daily dose in patients with moderate CKD. Furthermore, the pharmacodynamic response to SGLT2 inhibitors as assessed by urinary glucose excretion declines with increasing severity of renal impairment as assessed by a reduction in the estimated glomerular filtration rate. Nevertheless, the glucose-lowering efficacy and safety of SGLT2 inhibitors are almost comparable in patients with mild CKD as in patients with normal kidney function. In patients with moderate CKD, the efficacy tends to be dampened and safety concerns may occur. In patients with severe CKD, the use of SGLT2 inhibitors is contraindicated. Thus, prescribing information should be consulted regarding dosage adjustments or restrictions in the case of renal dysfunction for each SGLT2 inhibitor. The clinical impact of SGLT2 inhibitors on renal function and their potential to influence the course of diabetic nephropathy deserve attention because of preliminary favourable results in animal models.
Similar articles
- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Scheen AJ. Scheen AJ. Expert Opin Drug Metab Toxicol. 2014 May;10(5):647-63. doi: 10.1517/17425255.2014.873788. Epub 2014 Jan 3. Expert Opin Drug Metab Toxicol. 2014. PMID: 24387329 Review. - Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Tahara A, et al. J Pharmacol Sci. 2016 Mar;130(3):159-69. doi: 10.1016/j.jphs.2016.02.003. Epub 2016 Feb 15. J Pharmacol Sci. 2016. PMID: 26970780 - Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Macha S, et al. Diabetes Obes Metab. 2014 Mar;16(3):215-22. doi: 10.1111/dom.12182. Epub 2013 Aug 19. Diabetes Obes Metab. 2014. PMID: 23859488 Clinical Trial. - Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Schwartz SL, et al. Diabetes Technol Ther. 2011 Dec;13(12):1219-27. doi: 10.1089/dia.2011.0012. Epub 2011 Aug 19. Diabetes Technol Ther. 2011. PMID: 21854192 Clinical Trial.
Cited by
- SGLT2 inhibitors activate pantothenate kinase in the human heart.
Forelli N, Eaton D, Patel J, Bowman CE, Kawakami R, Kuznetsov IA, Li K, Brady C, Bedi K, Yang Y, Koya K, Megill E, Kanter DS, Smith LG, Bowman GR, Snyder N, Edwards J, Margulies K, Arany Z. Forelli N, et al. bioRxiv [Preprint]. 2024 Jul 27:2024.07.26.605401. doi: 10.1101/2024.07.26.605401. bioRxiv. 2024. PMID: 39091820 Free PMC article. Preprint. - SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.
Gajewska A, Wasiak J, Sapeda N, Młynarska E, Rysz J, Franczyk B. Gajewska A, et al. Int J Mol Sci. 2024 May 1;25(9):4959. doi: 10.3390/ijms25094959. Int J Mol Sci. 2024. PMID: 38732178 Free PMC article. Review. - Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis.
Zhang W, Yu M, Cheng G. Zhang W, et al. Front Pharmacol. 2024 Apr 17;15:1373314. doi: 10.3389/fphar.2024.1373314. eCollection 2024. Front Pharmacol. 2024. PMID: 38694909 Free PMC article. - SGLT2 inhibitors: Beyond glycemic control.
Hasan I, Rashid T, Jaikaransingh V, Heilig C, Abdel-Rahman EM, Awad AS. Hasan I, et al. J Clin Transl Endocrinol. 2024 Mar 12;35:100335. doi: 10.1016/j.jcte.2024.100335. eCollection 2024 Mar. J Clin Transl Endocrinol. 2024. PMID: 38525377 Free PMC article. - Long-Term Mortality and SGLT2 Inhibitors in Type 2 Diabetes with and without Renal Impairment: An Observational Cohort Study.
Al-Muhaiteeb A, Alahmad B, Abu-Farha M, Abubaker J, Thanaraj TA, Ali H, Al-Mulla F, Qaddoumi M. Al-Muhaiteeb A, et al. Med Princ Pract. 2024;33(3):251-259. doi: 10.1159/000537850. Epub 2024 Feb 15. Med Princ Pract. 2024. PMID: 38359814 Free PMC article.
References
- Ann Intern Med. 2013 Aug 20;159(4):262-74 - PubMed
- Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
- Diabetes Obes Metab. 2015 Feb;17(2):152-60 - PubMed
- Clin Drug Investig. 2014 Oct;34(10):731-42 - PubMed
- Drugs. 2014 Jun;74(8):939-44 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical